By Nick Paul Taylor
MacroGenics has closed a phase 2 clinical trial of its anti-cancer antibody enoblituzumab after learning of seven deaths potentially associated with hemorrhagic events. The setback means two of MacroGenics’ three attacks on B7-H3 have hit setbacks but the biotech is forging ahead with the third candidate.
read more
By Andrea Park
Medtronic has asked healthcare providers to immediately stop using more than 1 million catheters distributed across the U.S. and around the world after discovering a potential safety risk within the devices.
read more
Sponsored By: Parexel
The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics.
read more
By Dave Muoio
Northwell Health's president and CEO says the role of a leader is to ensure vying parties "coalesce around common values, programs and missions." He also stressed the need for healthcare organizations to remain committed when tackling complex, long-term goals such as Black maternal mortality.
read more
By Angus Liu
Amgen’s first-in-class KRAS inhibitor Lumakras has been grabbing attention even before its approval. Now, after closely watching the drug’s commercial performance in non-small cell lung cancer, one team of analysts is sounding an alarm ahead of key clinical trial data readouts.
read more
By Max Bayer
Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million.
read more
By Andrea Park
Lumos Diagnostics’ FebriDx point-of-care test will have to wait a bit longer to see the light of day in the U.S., as the Australian company announced Monday that its 510(k) submission to the FDA has been rejected.
read more
By Paige Minemyer
Tilak Mandadi will step into the position on July 25, and in the role will lead the healthcare giant's strategy around data, digital and technology, CVS said.
read more
By Fraiser Kansteiner
Legislation aimed at slashing high U.S. drug costs could undercut its own goals by depriving drugmakers of incentives for developing blockbuster medicines, plus lower-cost biosimilars and generics, several analysts and industry groups have warned.
read more
By Gabrielle Masson
Roche is handing over $55 million for the licensing rights to Ionis Pharmaceuticals’ rare kidney disease treatment candidate, an investigational med that the Big Pharma will advance into a phase 3 clinical trial.
read more
By Conor Hale
By working with medical headset maker Rods&Cones, Smith+Nephew hopes to offer technical support and real-time troubleshooting for its products from anywhere in the world.
read more
By Dave Muoio
Gov. Gavin Newsom announced on Twitter that a recently signed state budget allots $100 million for California to contract and make its own insulin.
read more
By Andrea Park
Cold and flu season may still be several months away in the northern hemisphere, but diagnostic test makers like Hologic and Thermo Fisher Scientific are taking no chances.
read more
By Annalee Armstrong
More than 100 women in biotech have signed on to a letter decrying the Supreme Court's ruling overturning Roe v. Wade. They say this is only the beginning of their activism.
read more
Sponsored by: Cognizant
Explore how Cognizant SIP helped Roche streamline its global feasibility process.
Sponsored by: Blue Matter Consulting
For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed.
Sponsored by: CG Life
Explore the new cell therapy handbook from Thermo Fisher Scientific.
Sponsored by: Catalent
What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?
Sponsored by: Thermo Fisher Scientific
Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals.
Sponsored by: Catalent
Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.
Sponsored by: Catalent
What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
